QiagenQGEN
About: Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Employees: 5,800
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
83% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 29
72% more call options, than puts
Call options by funds: $50.5M | Put options by funds: $29.4M
50% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 6 (+2) [Q3]
18% more repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 106
8% more funds holding
Funds holding: 300 [Q2] → 324 (+24) [Q3]
8% more capital invested
Capital invested by funds: $6.37B [Q2] → $6.87B (+$497M) [Q3]
1.53% less ownership
Funds ownership: 69.99% [Q2] → 68.46% (-1.53%) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Jefferies Tycho Peterson 42% 1-year accuracy 5 / 12 met price target | 20%upside $54 | Buy Assumed | 10 Dec 2024 |
Financial journalist opinion
Based on 12 articles about QGEN published over the past 30 days
